Patients From periodic medication review to proactive medication surv... As regimens, physiology, and clinical information change, medication review needs to become more responsive to those changes.
Patients The strategic opportunity: Owning the behaviour layer Behaviour is the layer that lifestyle, physical performance, and nutrition – together – occupy.
Patients Physical performance × nutrition — a multiplicative relation... Physical performance and nutrition are not just complementary, but biologically multiplicative.
Patients Longevity as the new health paradigm: The control system Nutrition shapes the biology of ageing; lifestyle determines how that biology is expressed
Patients Beyond weight loss: Exploring the impact of weight loss medi... It’s been less than two years since weight loss medications Wegovy and Mounjaro were approved in the UK to treat obesity.
Digital Highlighting the disruptors: Innovation for now and tomorrow... On Tuesday 19th March, pharmaphorum headed to King’s Place, London for the 10th annual WIRED Health conference - an event partnered with EY, Boston Scientific, and Lingo this year, which se
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.